Johnson & Johnson reported better than expected quarterly earnings, boosted by surging sales of a new drug for hepatitis C that are expected to evaporate in coming months due to competition from a more potent and convenient combination treatment.The diversified healthcare company on Tuesday said it earned $4.75 billion, or $1.66 per share, in the third quarter. That compared with $2.98 billion, or $1.04 per share, in the year-earlier period, when J&J took special charges related to legal expenses and merger-related costs.Excluding special items, J&J earned $1.50 per share. Analysts on average expected $1.45 per share, according to Thomson Reuters I/B/E/S.Company sales rose 5.1 percent to $18.47 billion, topping the average analyst estimate of $18.38 billion.
Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Shares of JNJ fell by 2.08% or $-2.11/share to $99.12. In the past year, the shares have traded as low as $86.09 and as high as $108.77. On average, 6714730 shares of JNJ exchange hands on a given day and today's volume is recorded at 10403202.
Thomson Reuters Corporation (Thomson Reuters) is a provider of information for the world?s businesses and professionals. Shares of TRI fell by 0.39% or $-0.14/share to $36.22. In the past year, the shares have traded as low as $33.21 and as high as $38.73. On average, 687882 shares of TRI exchange hands on a given day and today's volume is recorded at 818416.
Thomson Reuters Corporation (Thomson Reuters) is a provider of information for the world?s businesses and professionals. Shares of TRI fell by 0.8% or $-0.33/share to $40.77. In the past year, the shares have traded as low as $35.59 and as high as $42.10. On average, 675489 shares of TRI.TO exchange hands on a given day and today's volume is recorded at 1189950.
Source
